IMATINIB IN THE TREATMENT OF ADENOID CYSTIC CARCINOMAS OF THE HEAD AND NECK
Abstract
INTRODUCTION Adenoid cystic carcinomas in head and neck region are quite rare.
Majority of them originate from minor salivary glands. Adenoid cystic carcinomas are well known for
their indolent biological nature, protracted clinical course and late onset of distant metastases.
Surgery is the mainstay of treatment. In recurrent or metastatic disease, chemotherapy is an available
option. Several biological agents such as Imatinib have been tried with variable success rates in
these patients.We report a case series of seven patients diagnosed to have recurrent or metastatic
adenoid cystic carcinomas with CD 117 positivity, who had failed after receiving initial
treatment.METHODS AND MATERIALSThis was a retrospective study done on patients who were
diagnosed to have adenoid cystic carcinoma in the last ten years and treated with Imatinib in the
department of Radiotherapy. There were 7 patients who were started on Imatinib. All the patients had
histologically proven disease and CD 117 positivity .They all had either loco regionally advanced or
metastatic disease. The data was collected from patient records. Blood investigations, radiological
investigations were done in all the patients during follow up. Radiological assessment was done using
RECIST criteria and CTCAE version 4 criteria were used for toxicity assessment. RESULTSOut of
seven patients, data for response assessment was available for five patients. Among them three
patients had stable disease and two patients had progressive disease. Imatinib was well tolerated in
all patients.CONCLUSIONImatinib is an available treatment option in the treatment of recurrent or
metastatic adenoid cystic carcinomas of the head and neck.
Full Text:
PDFReferences
Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and
neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 1999
Feb;125(2):149–52.
Gates GA. Minor salivary gland tumors of the oral cavity. Otolaryngol Clin North Am. 1972
Jun;5(2):283–9.
Miglianico L, Eschwege F, Marandas P, Wibault P. Cervico-facial adenoid cystic carcinoma:
Study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol. 1987 May;13(5):673–8.
Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, et al. Imatinib mesylate
in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret
Hospital phase II consortium study. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jan 20;23(3):585–90.
Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic
carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance,
Epidemiology, and End Results data. Cancer. 2012 Sep 15;118(18):4444–51.
Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg.
Dec;164(6):623–8.
Khan AJ, DiGiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, et al. Adenoid cystic
carcinoma: a retrospective clinical review. Int J Cancer J Int Cancer. 2001 Jun 20;96(3):149–58.
Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ. The influence of positive margins
and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and
radiation. Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):619–26.
Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Ootsuki K, Terakado N, et al. Expression
of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an
immunohistochemical study. Anticancer Res. 1995 Dec;15(6B):2623–6.
Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, et al.
Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland
carcinoma: an indicator of aggressiveness. Laryngoscope. 1992 Aug;102(8):923–7.
Cho KJ, Lee SS, Lee YS. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein
expression in adenoid cystic carcinomas of the salivary glands. Head Neck. 1999 Aug;21(5):414–9.
Papadaki H, Finkelstein SD, Kounelis S, Bakker A, Swalsky PA, Kapadia SB. The role of p53
mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum Pathol.
Jun;27(6):567–72.
Simpson JR, Thawley SE, Matsuba HM. Adenoid cystic salivary gland carcinoma: treatment
with irradiation and surgery. Radiology. 1984 May;151(2):509–12.
Vikram B, Strong EW, Shah JP, Spiro RH. Radiation therapy in adenoid-cystic carcinoma. Int
J Radiat Oncol Biol Phys. 1984 Feb;10(2):221–3.
Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Management of minor
salivary gland carcinomas. Int J Radiat Oncol. 1996 Jun 1;35(3):443–54.
Tannock IF, Sutherland DJ. Chemotherapy for adenocystic carcinoma. Cancer. 1980 Aug
;46(3):452–4.
Hill ME, Constenla DO, A’Hern RP, Henk JM, Rhys-Evans P, Breach N, et al. Cisplatin and 5-
fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol. 1997
Jul;33(4):275–8.
Vermorken JB, Verweij J, de Mulder PH, Cognetti F, Clavel M, Rodenhuis S, et al. Epirubicin
in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II
study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol Off J Eur Soc Med Oncol
ESMO. 1993 Nov;4(9):785–8.
Airoldi M, Fornari G, Pedani F, Marchionatti S, Gabriele P, Succo G, et al. Paclitaxel and
carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000 Oct;20(5C):3781–3.
Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, et al. Phase II
randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent
salivary gland malignancies. Cancer. 2001 Feb 1;91(3):541–7.
Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of
c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol Off J United States Can Acad Pathol Inc.
Oct;12(10):956–60.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib
compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic
myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994–1004.
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval
summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant
gastrointestinal stromal tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2002
Oct;8(10):3034–8.
Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of
Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007
Jan;43(1):33–6.
Ochel H-J, Gademann G, Röcken C, Wördehoff H. Effects of imatinib mesylate on adenoid
cystic carcinomas. Anticancer Res. 2005 Oct;25(5):3659–64.
Alcedo JC, Fábrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid
cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck. 2004
Sep;26(9):829–31.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
Oxf Engl 1990. 2009 Jan;45(2):228–47.
Matsuo M, Rikimaru F, Higaki Y. [Clinical study on 72 cases of adenoid cystic carcinoma].
Nihon Jibiinkoka Gakkai Kaiho. 2013 Jan;116(1):10–6.
Frierson HF Jr, El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, et al. Large scale
molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am
J Pathol. 2002 Oct;161(4):1315–23.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University